Immunotherapy and innate immunity targets are at the heart of the search for long-term, high quality of life responses for patients Bristol-Myers Squibb France and Innate Pharma are pleased to...

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces revenue of 3.0 million euros for the first quarter of 2012, compared with 1.0 million euros for the same period in 2011...

Panel of internationally renowned speakers including Nobel Prize winners in Medicine 2011 and Philippe Kourilsky, professor at the Collège de France, as moderator; Dedicated website www.immunite-innee...

Collaboration and licence agreement signed with Bristol-Myers Squibb for lead program Strengthened position in the innate immunity field Total cash increased to €46.6 million from €34.6 million at the...

Revenue of 11.7 million euros including payments from partners Bristol-Myers Squibb and Novo Nordisk A/S as well as research tax credit Strong cash position with 46.6 million euros in cash, cash...

Innate Pharma co-owns intellectual property rights relating to the NKp46 receptor with INSERM, the French National Institute of Health and Medical Research Endorses Innate Pharma’s fruitful...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today its tentative financial...

Turnover of 3.1 million euros Cash position as at September 30, 2011 of 49.3 million euros Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class...